# Helicore Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/helicore-biopharma

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.helicore.com
- Total disclosed funding: $15M
- Latest round: Series A (Jan 10, 2024)
- Investors on record: 4

## About

Based in California, US, and founded in 2025 and led by CEO Gerrit Klaerner, Helicore Biopharma Inc. is a biopharmaceutical company that focuses on discovering and developing novel therapies for obesity. In January 2025, Helicore Biopharma Inc. raised USD 65 million in Series A funding co-led by OrbiMed Advisors and Versant Ventures, with participation from Longitude Capital and Wellington Management.

Helicore Biopharma Inc. specializes in the discovery and development of therapies focused on solving obesity. The company's product offerings include treatment modalities designed to alter metabolic pathways associated with weight management. These therapeutic solutions target various aspects of obesity, including appetite regulation and energy expenditure, providing end users with alternatives to traditional weight loss methods. The firm serves various clients, including healthcare providers, researchers, and patients.

## Funding rounds

- Series A, Jan 10, 2024, $15M — OrbiMed Advisors, Versant Ventures, Wellington Management, Longitude Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A